In June 2026, India’s Central Drugs Standard Control Organisation (CDSCO) issued a directive requiring all pharmaceutical manufacturers in India to maintain a robust pharmacovigilance system for reporting adverse events (AEs) associated with their drug products. This regulatory move marks a significant step forward in strengthening drug safety oversight across the Indian pharmaceutical industry, which supplies generic medicines to over 200 countries worldwide.
What the CDSCO Directive Requires
The CDSCO’s June 2026 directive asks drug manufacturers to establish and maintain a pharmacovigilance (PV) system capable of collecting, processing, and submitting reports on suspected adverse drug reactions (ADRs). Key provisions include:
- Mandatory PV system: Every drug manufacturer must have a dedicated system for tracking adverse events linked to their products.
- Continuous reporting: Manufacturers must report adverse events as soon as they are identified, not waiting for accumulated data, ensuring faster detection of safety signals.
- Adverse Drug Reaction (ADR) reporting: Both serious and non-serious ADRs must be captured and submitted to CDSCO through the national pharmacovigilance programme (PvPI).
- Comprehensive coverage: The directive covers all drug products manufactured in India, including generic medicines, branded generics, formulations, and active pharmaceutical ingredients (APIs).
Why This Matters for Global Buyers
India is the world’s largest provider of generic medicines, supplying a significant share of essential medicines to the United States, Africa, Latin America, and Southeast Asia. For international buyers and procurement agencies, the CDSCO’s new pharmacovigilance mandate offers several important implications:
- Stronger safety net: A mandatory AE reporting system means safety issues with Indian generic medicines are more likely to be detected, documented, and addressed systematically, rather than identified only after harm has occurred.
- Traceability: When a safety signal is detected, a functioning PV system allows regulators to trace the problem back to the manufacturer, the batch, and the specific formulation, making recalls and corrective actions faster and more targeted.
- Regulatory credibility: Countries that rely on Indian generics for their medicine supply chains gain greater confidence knowing that the country of origin has a mandated post-market surveillance infrastructure in place.
Connecting Pharmacovigilance to WHO-GMP Standards
Pharmacovigilance does not operate in isolation. It complements the existing WHO-GMP (World Health Organization Good Manufacturing Practice) framework that already governs manufacturing quality in India. While WHO-GMP ensures that drugs are produced under controlled, hygienic, and consistent conditions, pharmacovigilance adds the essential post-market dimension, monitoring how drugs perform once they reach patients in real-world conditions.
Buyers who already request WHO-GMP certificates from Indian manufacturers can now ask a follow-up question: does the manufacturer operate a pharmacovigilance system, and can they demonstrate ADR reporting compliance with CDSCO requirements? This dual-layer verification, manufacturing quality plus post-market safety surveillance, represents the gold standard for responsible medicine procurement.
What Buyers Should Look For
For procurement officers, hospital formularies, and government tenders evaluating Indian generic medicines, the CDSCO pharmacovigilance mandate adds a new dimension to due diligence. Here are practical steps buyers can take:
- Ask for PV compliance documentation: Request evidence that the manufacturer has established a pharmacovigilance system and is actively reporting ADRs to CDSCO’s PvPI platform.
- Check the manufacturer’s CDSCO registration: Verify that the manufacturer holds a valid manufacturing license and product approval from CDSCO. A functioning PV system is a regulatory obligation, not an optional add-on.
- Review the product’s safety record: For medicines you are considering sourcing, check whether any safety advisories, pharmacovigilance signals, or regulatory communications have been issued by CDSCO or international regulators such as the US FDA or EMA.
- Use trusted networks: For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory, which includes distributors who adhere to quality and transparency standards.
Looking Ahead: Building a Culture of Drug Safety
The CDSCO’s pharmacovigilance mandate represents a maturing regulatory landscape in India. As the industry moves from voluntary PV participation to a mandatory framework, the expectation is that adverse event reporting will become more systematic, comprehensive, and timely, benefiting patients, regulators, and international buyers alike.
For the global generic medicine market, this is a positive development. Drug safety is not just about manufacturing quality at the point of production; it is about sustained vigilance throughout a product’s lifecycle. India’s commitment to building that lifecycle safety infrastructure strengthens the foundation on which the world’s generic medicine supply chains depend.
For more information, contact IMSDA at contact@indiamedicine.org.